Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avutometinib, Defactinib, and Cetuximab in Advanced Colorectal Cancer
NCT06369259Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2025
- Primary completion
- Feb 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of avutometinib in colorectal cancer (CRC), sponsored by University of Texas MD Anderson Cancer Center. Started Feb 2025; status: recruiting.
02
Drugs
avutometinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06369259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06369259.